Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.20 USD
+0.13 (12.15%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $1.19 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Price, Consensus and EPS Surprise
BFRI 1.20 +0.13(12.15%)
Will BFRI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BFRI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BFRI
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
BFRI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Biofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should Know
Other News for BFRI
Biofrontera Unveils RhodoLEDĀ® XL Lamp, Eyes Market Growth
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLEDĀ® XL Lamp
Biofrontera Inc. announces launch of RhodoLED XL lamp
Biofrontera Stockholders Approve Key Governance Decisions
Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)